Breast Cancer

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.

When it comes to living with cancer, your nurses make a difference.

Breast cancer surgery can disfigure the body in some way, and often the scars are more than skin deep, which may worsen by the actions of others.

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy.

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09.

Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer.

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when compared with Faslodex.

After being diagnosed with breast cancer at 39, I learned to advocate for myself, transforming fear into fierce resolve and purpose through every step.

Heather Patenaude, B.S.N., RN, displays the highest level of technical skills necessary to provide compassionate care to her patients.

After my breast cancer treatment, I started a clothing bank to give others free access to recovery items like post-surgery shirts and pillows.

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.

When I saw a study about using AI facial recognition in cancer decision-making headlines, I decided to try my own informal, non-scientific experiment.

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma patient populations, respectively.

I’ll never forget the unnamed nurse who stayed calm and gentle while treating me during a dangerous post-surgery infection that could have ended my life.

Recent phase 2 data support combination treatment with samuraciclib for those with HR+ advanced breast cancer following prior CDK4/6 inhibitor therapy.

Dr. Hyman B. Muss discusses the unique challenges that older patients with breast cancer face during and after treatment for their disease.

Treatment with Perjeta, Herceptin and chemotherapy post-surgery led to a significant overall survival benefit in HER2-positive early-stage breast cancer.

Summer heat can worsen my lymphedema, but I’ve learned simple ways to stay cool, reduce swelling and protect my arms — here’s what helps me most.

Dr. Hyman B. Muss discusses the unique facets of care that should inform personalized treatment decision-making for older patients with breast cancer.

I’m 22 years out from breast cancer and forever grateful for the nurses who gave me not just treatment but friendship, laughter and a community of hope.

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk HER2-positive early-stage breast cancer.

New results from a breast cancer-related lymphedema study show the importance of measuring fluid and body composition before treatment begins.

Breast cancer treatment is a physical, emotional, and mental challenge. Facing cancer and its side effects demands extraordinary physical, emotional, and spiritual stamina.

A breast cancer diagnosis brings about many losses.

A chance meeting with my childhood friend reminded me — and others — that living with cancer means taking things one day at a time.

The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.

I reflect on how a generic mammogram reminder overlooked my experience as a breast cancer survivor and how thoughtful messaging could make a difference.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.